Indefinite Delivery Contract SPE2DU25D9422

The federal contract IDV award SPE2DU25D9422 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories such as injections, tablets, creams, auto-injectors, and specialty medications.

This IDC is part of the DLA's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) effort, a $30.3 billion unrestricted and fully competitive acquisition to establish multiple regional prime vendor contracts for providing worldwide pharmaceutical support to the Department of Defense, United States Coast Guard, and other government agencies. The PPV-G GEN V solicitation, expected to be issued in March 2024, will award at least three different contractors to serve as primary and backup suppliers, ensuring resiliency and access to vital pharmaceuticals during contingencies or natural disasters.